Anaphylactic Reaction to Oral Cefaclor in a Child

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Anaphylactic Reaction to Oral Cefaclor in a Child ABSTRACT. Adverse drug reactions are a common diphenhydramine. He did not have any associated respiratory clinical problem. It has been estimated1 that 6% to 15% of symptoms, hypotension, or gastrointestinal symptoms. He had hospitalized patients experience some sort of adverse been treated with cefaclor on two previous additional occasions, drug reaction. Clinical manifestations of adverse drug without adverse reaction. Two months later, the patient redeveloped otitis media, and reactions include skin rash; a serum sickness-like reac- unfortunately, ignorant to the previous reaction, cefaclor was tion; drug fever; pulmonary, hepatic, and renal involve- prescribed. Thirty seconds after ingesting the first dose of the ment; and systemic anaphylaxis. Many of these adverse drug, he developed a severe systemic reaction comprised of vom- events are not immunologically mediated. Actual allergic iting, generalized hives, shortness of breath, and wheezing with or immunologic drug reactions probably account for grunting. He lost consciousness on the way to the local hospital. <25% of adverse drug reactions overall.1 The patient was not on any other medication at this time. He was Antibiotics are one of the major contributors to drug treated on arrival with subcutaneous epinephrine, intravenous hypersensitivity. Cefaclor, an oral second-generation diphenhydramine, intravenous fluids, and inhaled salbutamol cephalosporin with a b-lactam ring, is used against var- with oxygen. He was noted to have tachypnea (60 breaths/ minute); however, his blood pressure was unreported. He was ious infectious diseases of the respiratory tract, especially observed for 24 hours and discharged from the hospital in stable in children. Several cases of cefaclor hypersensitivity condition. Acute serum tryptase and urinary leukotriene E4 levels 2,3 have been reported. The most common presentations were not measured. are either erythematous or papular eruptions, although Subsequently we tested the patient for penicillin and cefaclor. serum sickness-like reactions have also been described. All penicillin tests were negative, including the epicutaneous, Anaphylactic reactions, although rare, have been ob- intradermal, and oral challenges. However, epicutaneous prick served in adults. Here we report a case of anaphylactic testing with histamine revealed a wheal-and-flare reaction of a 5 3 1 5 mm induration; and there was an 8 3 10 mm induration at the reaction to cefaclor in a 2 ⁄2-year-old patient. Pediatrics 1999;103(4). URL: http://www.pediatrics.org/cgi/content/ site of the cefaclor epicutaneous test. Epicutaneous and intrader- e mal testing with cefuroxime, cefazolin, and ceftazidime were also full/103/4/ 50; anaphylaxis, cefaclor, penicillin, cephalos- negative. A simultaneous cefaclor skin test on a control, whom porine, case report. was noted to be an atopic individual, was negative. METHODS efaclor, in a 1-mg/mL solution, was used for DISCUSSION epicutaneous prick testing. We also used ce- Hypersensitivity to cefaclor has been recognized Cfuroxime, cefazolin, and ceftazidime in a 2.5- since its early clinical introduction. In 1981, Kammer4 mg/mL solution for testing. A solution of phos- reviewed more than 3000 adult and pediatric pa- phate-buffered physiologic saline at pH 7.4 with tients treated with cefaclor and found an incidence of 0.4% phenol was used for negative control. For pos- hypersensitivity of 1.1%. Rash and diffuse pruritus itive control, we used histamine 1/200 in water were the most common findings. In 1980, McLinn5 (Bencard Allergy Laboratories, Mississauga, Ontario, reviewed the efficacy of cefaclor in the treatment of Canada). otitis media and noted no serious adverse reactions, We performed a battery of penicillin prick, intra- except for one case of vascular purpura. This oc- dermal, and oral challenge tests. As major determi- curred during the sixth day of treatment of a 5-year- nants, we used penicillin G at 1000 U/mL and 100 old boy with otitis media, who was taking cefaclor, U/mL, and benzylpenicilloyl polylysine 6 3 1025 M 250 mg, three times a day. Other reports suggested a (Pre-Pen; Richmond Pharmaceuticals, Richmond serum sickness-like syndrome, with symptoms in- Hill, Ontario, Canada). For minor determinants, we cluding malaise, fever, cutaneous eruption, and ar- used penicilloate and penicilloate sodium 10 mM. thralgias.6–8 For oral challenge, 250 mg of penicillin G was given. Penicillin remains the most common cause of The patient’s parent gave consent for us to carry out drug-induced anaphylaxis. It has been estimated2 the tests, which were done according to the guide- that nearly 75% of fatal anaphylactic reactions result lines of our hospital ethics board. from the administration of penicillin. Anaphylaxis because of cefaclor is rare. Nishioka and colleagues3 CASE REPORT described 3 adult patients who developed urticarial A 27-month-old, nonatopic, white boy, previously healthy, was rashes with asphyxiation immediately after an ad- referred to our allergy/adverse drug reaction service for assess- ministration of cefaclor. In 1988, Hama and Mori9 ment of his anaphylactic reaction to cefaclor. reported 4 adults with anaphylactic reactions. But At the age of 2 years, he developed generalized hives 1 day after ingesting cefaclor suspension for otitis media. The eruption never before were similar reactions reported in the was pruritic. The rash resolved the same day, after one dose of pediatric age group. We report a case of anaphylaxis to cefaclor in a child who developed urticarial rash, vomiting, respi- Received for publication May 15, 1998; accepted Nov 16, 1998. ratory distress, and loss of consciousness immedi- Reprint requests to (C.M.R.) Hospital for Sick Children, Division of Immu- nology/Allergy, 555 University Ave, Toronto, Ontario, M5G 1X8, Canada. ately after cefaclor ingestion, requiring immediate PEDIATRICS (ISSN 0031 4005). Copyright © 1999 by the American Acad- treatment. This reaction to cefaclor is most likely to emy of Pediatrics. be IgE-mediated, which was confirmed by a strongly http://www.pediatrics.org/cgi/content/full/103/4/Downloaded from www.aappublications.org/newse50 by guestPEDIATRICS on September Vol. 26, 2021 103 No. 4 April 1999 1of2 positive epicutaneous prick test. Because the break- Masoud Grouhi, MD down products of cefaclor are unknown, in vitro David Hummel, MD testing for this drug was not done. However, the Chaim M. Roifman, MD positive epicutaneous test is indicative of IgE in- University of Toronto volvement. Furthermore these IgE antibodies are Department of Paediatrics, Division of Immunology/ more likely to be side chain specific to cefaclor be- Allergy Hospital for Sick Children cause our patient did not show any reaction to other Toronto, Ontario, Canada M5G 1X8 cephalosporins including cefuroxime, cefazolin, and ceftazidime. Our patient gradually developed hypersensitivity REFERENCES to cefaclor; his first three exposures to cefaclor were 1. Patterson R, Anderson J. Allergic reactions to drugs and biologic agents. without significant reactions. This presentation is un- JAMA. 1982;248:2637–2645 usual compared with anaphylaxis from penicillin, 2. Shelter AL. Anaphylaxis. J Allergy Clin Immunol. 1985;75:227–233 3. Nishioka K, Katayama I, Kobayashi Y, Takijiri C. Anaphylaxis due to which usually appears after the first or second expo- cefaclor hypersensitivity. J Dermatol. 1986;13:226–227 sure. There is a risk of cross-reactivity between pen- 4. Kammer RB. Cefaclor in management of streptococcal pharyngitis, icillin and cephalosporins, occurring in 4% to 15% of otitis media, and skin infections. Ann Otol Rhinol Laryngol. 1981;90: cases10–12; therefore, most clinicians avoid cephalo- 79–81 sporins for patients with a history of immediate re- 5. McLinn SE. Cefaclor in the treatment of otitis media and pharyngitis in 12 children. Am J Dis Child. 1980;134:560–563 actions to a penicillin. In our patient penicillin test- 6. Lawley TJ, Frank MM. Immune complexes and allergic diseases. In: ing (including oral administration of penicillin was Middleton E, Reed CE, Ellis EF, Adkinson NF, eds. Allergy: Principles negative). and Practice. St Louis, MO: CV Mosby Co; 1993:990–1006 7. Murray DL, Singer DA, Singer AB. Cefaclor: a cluster of adverse reac- CONCLUSION tions. N Engl J Med. 1980;303:1003 8. Swedish Adverse Drug Reaction Advisory Committee. Hypersensitiv- In summary, we report a case of an anaphylactic ity reactions to cefaclor. Bull SADRAC. 1986;47:2–3 reaction to cefaclor in the pediatric population. Be- 9. Hama R, Mori K. High incidence of anaphylactic reaction to cefaclor. cause cefaclor is widely used in children for common Lancet. 1988;1:1331 infections such as otitis media, we will likely see 10. Anderson JA. Cross-sensitivity to cephalosporins in patients allergic to more cases of anaphylactic reaction to this antibiotic. penicillin. Pediatr Infect Dis J. 1986;5:557–561 11. Levine BB. Antigenicity and cross-reactivity of penicillin and cephalo- Physicians should anticipate the possibility of ana- sporins. J Infect Dis. 1973;128:S364–S366 phylactic reaction in children treated with this agent, 12. Lin RY. A perspective on penicillin allergy. Arch Intern Med. 1992;152: particularly in cases of multiple exposure. 930–937 2of2 ANAPHYLACTICDownloaded REACTION from TOwww.aappublications.org/news ORAL CEFACLOR IN by A guest CHILD on September 26, 2021 Anaphylactic Reaction to Oral Cefaclor in a Child Masoud Grouhi, David Hummel
Recommended publications
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application

    Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application

    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
  • Empiric Antimicrobial Therapy for Diabetic Foot Infection

    Empiric Antimicrobial Therapy for Diabetic Foot Infection

    Empiric Antimicrobial Therapy for Diabetic Foot Infection (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2019) Infection Severity Preferred Empiric Regimens Alternative Regimens Comments Mild Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Outpatient management • Cellulitis less than 2 cm and • cephalexin 500 – 1000 mg PO q6h*,a OR • clindamycin 300 – 450 mg PO q6h (only if recommended ,a • cefadroxil 500 – 1000 mg PO q12h* severe delayed reaction to a beta-lactam) without involvement of deeper • Tailor regimen based on culture tissues and susceptibility results and True immediate allergy to a beta-lactam at MRSA Suspected: • Non-limb threatening patient response risk of cross reactivity with cephalexin or • doxycycline 200 mg PO for 1 dose then • No signs of sepsis cefadroxil: 100 mg PO q12h OR • cefuroxime 500 mg PO q8–12h*,b • sulfamethoxazole+trimethoprim 800+160 mg to 1600+320 mg PO q12h*,f Wound greater than 4 weeks duration:d Wound greater than 4 weeks duratione • amoxicillin+clavulanate 875/125 mg PO and MRSA suspected: q12h*,c OR • doxycycline 200 mg PO for 1 dose then • cefuroxime 500 mg PO q8–12h*,b AND 100 mg PO q12h AND metroNIDAZOLE metroNIDAZOLE 500 mg PO q12h 500 mg PO q12h OR • sulfamethoxazole+trimethoprim 800+160 mg to 1600/320 mg PO q12h*,f AND metroNIDAZOLE 500 mg PO q12h Moderate Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Initial management with • Cellulitis greater than 2 cm or • ceFAZolin 2 g IV q8h*,b OR • levoFLOXacin 750
  • Cefalexin in the WHO Essential Medicines List for Children Reject

    Cefalexin in the WHO Essential Medicines List for Children Reject

    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
  • 'Cephalosporin Allergy' Label Is Misleading

    'Cephalosporin Allergy' Label Is Misleading

    VOLUME 41 : NUMBER 2 : APRIL 2018 ARTICLE ‘Cephalosporin allergy’ label is misleading Carlo L Yuson SUMMARY Immunology registrar1 Constance H Katelaris Penicillins and cephalosporins can cause a similar spectrum of allergic reactions at a similar rate. Immunologist2 Cross-reactive allergy between penicillins and cephalosporins is rare, as is cross-reaction within William B Smith 1 the cephalosporin group. Patients should therefore not be labelled ‘cephalosporin-allergic’. Immunologist Cross-reactive allergy may occur between cephalosporins (and penicillins) which share similar 1 Clinical Immunology and side chains. Allergy Royal Adelaide Hospital Generally, a history of a penicillin allergy should not rule out the use of cephalosporins, and a 2 Immunology and Allergy history of a specific cephalosporin allergy should not rule out the use of other cephalosporins. Unit Campbelltown Hospital Specialist advice or further investigations may be required when the index reaction was New South Wales anaphylaxis or a severe cutaneous adverse reaction, or when the antibiotics in question share common side chains. Keywords When recording a drug allergy in the patient’s records, it is important to identify the specific drug cephalosporin allergy, hypersensitivity, penicillin suspected (or confirmed), along with the date and nature of the adverse reaction. Records need allergy to be updated after a negative drug challenge. Aust Prescr 2018;41:37–41 as Stevens-Johnson syndrome, toxic epidermal Introduction https://doi.org/10.18773/ necrolysis or acute generalised exanthematous To label an individual with a ‘cephalosporin allergy’ austprescr.2018.008 pustulosis or organ hypersensitivity). is misleading. Given the structural diversity of the cephalosporin family, hypersensitivity is seldom a Structural chemistry and allergy Corrected 3 December 2018 class effect but is much more likely to relate to the Immunological reactivity to small molecules such This is the corrected individual drug.
  • Clavulanic Acid, and Cefaclor Against Experimental Streptococcus Pneumoniae Respiratory Infections in Mice JOHN GISBY,* BARBARA J

    Clavulanic Acid, and Cefaclor Against Experimental Streptococcus Pneumoniae Respiratory Infections in Mice JOHN GISBY,* BARBARA J

    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1991, p. 831-836 Vol. 35, No. 5 0066-4804/91/050831-06$02.00/0 Copyright © 1991, American Society for Microbiology Comparative Efficacies of Ciprofloxacin, Amoxicillin, Amoxicillin- Clavulanic Acid, and Cefaclor against Experimental Streptococcus pneumoniae Respiratory Infections in Mice JOHN GISBY,* BARBARA J. WIGHTMAN, AND ANGELA S. BEALE SmithKline Beecham Pharmaceuticals, Brockham Park, Betchworth, Surrey RH3 7AJ, England Received 24 October 1990/Accepted 13 February 1991 Experimental respiratory infections were established in mice by intranasal inoculation of Streptococcus pneumoniae. Inoculation of 107 CFU of either S. pneumoniae 1629 or S. pneumoniae 7 produced a fatal pneumonia in nontreated mice 2 to 3 days after infection. Oral therapy was commenced 1 h after infection and was continued three times a day for 2 days. The doses used in mice produced peak concentrations in serum and lung tissue similar to those measured in humans. Ciprofloxacin failed to eliminate either strain of pneumo- coccus from mouse lungs at any of the doses tested (40, 80, or 160 mg/kg of body weight) by the end of therapy (33 h). Mice that received ciprofloxacin at 160 mg/kg were clear of S. pneumoniae 7 5 days later, whereas persistence and regrowth of S. pneumoniae 1629 resulted in the death of 20% of animals treated with ciprofloxacin. Therapy with cefaclor (20 mg/kg) produced an effect similar to that of ciprofloxacin. In contrast, amoxicillin (10 and 20 mg/kg) and amoxicillin-clavulanic acid (10/5 and 20/10 mg/kg) were significantly (P < 0.05) more effective in eliminating both strains of S.
  • Management of Penicillin and Beta-Lactam Allergy

    Management of Penicillin and Beta-Lactam Allergy

    Management of Penicillin and Beta-Lactam Allergy (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Key Points • Beta-lactams are generally safe; allergic and adverse drug reactions are over diagnosed and over reported • Nonpruritic, nonurticarial rashes occur in up to 10% of patients receiving penicillins. These rashes are usually not allergic and are not a contraindication to the use of a different beta-lactam • The frequently cited risk of 8 to 10% cross-reactivity between penicillins and cephalosporins is an overestimate based on studies from the 1970’s that are now considered flawed • Expect new intolerances (i.e. any allergy or adverse reaction reported in a drug allergy field) to be reported after 0.5 to 4% of all antimicrobial courses depending on the gender and specific antimicrobial. Expect a higher incidence of new intolerances in patients with three or more prior medication intolerances1 • For type-1 immediate hypersensitivity reactions (IgE-mediated), cross-reactivity among penicillins (table 1) is expected due to similar core structure and/or major/minor antigenic determinants, use not recommended without desensitization • For type-1 immediate hypersensitivity reactions, cross-reactivity between penicillins (table 1) and cephalosporins is due to similarities in the side chains; risk of cross-reactivity will only be significant between penicillins and cephalosporins with similar side chains • Only type-1 immediate hypersensitivity to a penicillin manifesting as anaphylaxis, bronchospasm,
  • Cephalosporins Can Be Prescribed Safely for Penicillin-Allergic Patients ▲

    Cephalosporins Can Be Prescribed Safely for Penicillin-Allergic Patients ▲

    JFP_0206_AE_Pichichero.Final 1/23/06 1:26 PM Page 106 APPLIED EVIDENCE New research findings that are changing clinical practice Michael E. Pichichero, MD University of Rochester Cephalosporins can be Medical Center, Rochester, NY prescribed safely for penicillin-allergic patients Practice recommendations an allergic reaction to cephalosporins, ■ The widely quoted cross-allergy risk compared with the incidence of a primary of 10% between penicillin and (and unrelated) cephalosporin allergy. cephalosporins is a myth (A). Most people produce IgG and IgM antibodies in response to exposure to ■ Cephalothin, cephalexin, cefadroxil, penicillin1 that may cross-react with and cefazolin confer an increased risk cephalosporin antigens.2 The presence of of allergic reaction among patients these antibodies does not predict allergic, with penicillin allergy (B). IgE cross-sensitivity to a cephalosporin. ■ Cefprozil, cefuroxime, cefpodoxime, Even penicillin skin testing is generally not ceftazidime, and ceftriaxone do not predictive of cephalosporin allergy.3 increase risk of an allergic reaction (B). Reliably predicting cross-reactivity ndoubtedly you have patients who A comprehensive review of the evidence say they are allergic to penicillin shows that the attributable risk of a cross- U but have difficulty recalling details reactive allergic reaction varies and is of the reactions they experienced. To be strongest when the chemical side chain of safe, we often label these patients as peni- the specific cephalosporin is similar to that cillin-allergic without further questioning of penicillin or amoxicillin. and withhold not only penicillins but Administration of cephalothin, cepha- cephalosporins due to concerns about lexin, cefadroxil, and cefazolin in penicillin- potential cross-reactivity and resultant IgE- allergic patients is associated with a mediated, type I reactions.
  • The Use of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities

    The Use of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities

    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Graduate School Professional Papers 2010 The seU of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities Joshua Bryant Phillips The University of Montana Let us know how access to this document benefits ouy . Follow this and additional works at: https://scholarworks.umt.edu/etd Recommended Citation Phillips, Joshua Bryant, "The sU e of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities" (2010). Graduate Student Theses, Dissertations, & Professional Papers. 1100. https://scholarworks.umt.edu/etd/1100 This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. THE USE OF NATURAL PRODUCT SUBSTRATES FOR THE SYNTHESIS OF LIBRARIES OF BIOLOGICALLY ACTIVE, NEW CHEMICAL ENTITIES by Joshua Bryant Phillips B.S. Chemistry, Northern Arizona University, 2002 B.S. Microbiology (health pre-professional), Northern Arizona University, 2002 Presented in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chemistry The University of Montana June 2010 Phillips, Joshua Bryant Ph.D., June 2010 Chemistry THE USE OF NATURAL PRODUCT SUBSTRATES FOR THE SYNTHESIS OF LIBRARIES OF BIOLOGICALLY ACTIVE, NEW CHEMICAL ENTITIES Advisor: Dr. Nigel D. Priestley Chairperson: Dr. Bruce Bowler ABSTRACT Since Alexander Fleming first noted the killing of a bacterial culture by a mold, antibiotics have revolutionized medicine, being able to treat, and often cure life-threatening illnesses and making surgical procedures possible by eliminating the possibility of opportunistic infection.
  • Antimicrobial Treatment Guidelines for Common Infections

    Antimicrobial Treatment Guidelines for Common Infections

    Antimicrobial Treatment Guidelines for Common Infections June 2016 Published by: The NB Provincial Health Authorities Anti-infective Stewardship Committee under the direction of the Drugs and Therapeutics Committee Introduction: These clinical guidelines have been developed or endorsed by the NB Provincial Health Authorities Anti-infective Stewardship Committee and its Working Group, a sub- committee of the New Brunswick Drugs and Therapeutics Committee. Local antibiotic resistance patterns and input from local infectious disease specialists, medical microbiologists, pharmacists and other physician specialists were considered in their development. These guidelines provide general recommendations for appropriate antibiotic use in specific infectious diseases and are not a substitute for clinical judgment. Website Links For Horizon Physicians and Staff: http://skyline/patientcare/antimicrobial For Vitalité Physicians and Staff: http://boulevard/FR/patientcare/antimicrobial To contact us: [email protected] When prescribing antimicrobials: Carefully consider if an antimicrobial is truly warranted in the given clinical situation Consult local antibiograms when selecting empiric therapy Include a documented indication, appropriate dose, route and the planned duration of therapy in all antimicrobial drug orders Obtain microbiological cultures before the administration of antibiotics (when possible) Reassess therapy after 24-72 hours to determine if antibiotic therapy is still warranted or effective for the given organism or
  • About Your Medication CEFACLOR

    About Your Medication CEFACLOR

    About your medication CEFACLOR (Ceclor®, Ceclor-CD®, Keflor®, Keflor-CD® 375mg SR tablets, 125mg/5mL suspension 250mg/5mL suspension) Other brands may be available The brand you have been given is: ____________________________ WHAT IS CEFACLOR? Cefaclor is an antibiotic. It belongs to a group of medications called cephalosporins. It is only available on a doctor’s prescription. WHAT IS IT FOR? Cefaclor is used to treat bacterial infections. Some types of infections it is used for are: • ears, nose, throat and tonsils (upper respiratory tract) • chest and lungs (lower respiratory tract) • bladder and kidneys (urinary tract) • skin. HOW TO TAKE THIS MEDICINE It is important that this medication is taken only as directed, and not given to other people. Cefaclor mixture is usually given two or three times a day. The tablets are usually given twice a day. The tablets should be swallowed whole. It does not matter if cefaclor is given with food or on an empty stomach. It may be given with food if stomach upsets occur. It is important to give the full course of treatment. If you are using the mixture, measure the dose accurately with a dropper, syringe or measuring glass / spoon. WHAT TO DO IF A DOSE IS MISSED If you miss a dose of cefaclor it can be given as soon as you remember. If it is close to the next dose, leave out the missed dose and continue as usual from that dose. Do not double up on any doses. STORING THE MEDICINE It is important to keep cefaclor away out of the reach of children.
  • 1 Cephalosporins and Vancomycin

    1 Cephalosporins and Vancomycin

    Alice Prince CEPHALOSPORINS AND VANCOMYCIN CEPHALOSPORINS These compounds are closely related in structure, mechanism of action, spectrum of activity and pharmacology to the penicillins. They are produced by fungi and synthetic modification. I. CHEMISTRY Contains 6-membered dihydrothiazine ring. Substitutions at position 3 generally affect pharmacology; substitutions at position 7 affect antibacterial activity, but this is not invariably true. 1 II. MECHANISM OF ACTION Cephalosporins are bactericidal. They inhibit enzymatic reactions necessary for stable bacterial cell walls by binding to PBPs. Bacterial cells must be growing. III. PHARMACOLOGIC PROPERTIES OF CEPHALOSPORINS Peak blood level Percentage Drug (µg/ml) Protein Binding T½ (hr) [CSF] µg/ml Cefazolin 1g 188 70 - 85% 1.4 ---------------- Cefuroxime 1.5g 100 50% 1.3 1.1 - 18 Cefoxitin 1g 110 70% 0.7-0.9 ---------------- Cefotaxime 1g 100 13 - 38% 1.0 6 – 11 (2g)* Ceftriaxone 1g 150 83 - 96% 5.8-8.7 1.3 - 44 Ceftazidime 1g 90 < 10% 1.9 2 – 42 *non-inflamed meninges CSF level 0.01-0.7 µg/ml IV. MECHANISM OF RESISTANCE TO CEPHALOSPORINS A. Failure to reach receptor sites, permeability. B. Destroyed by β-lactamase. Some gram-negative bacteria produce large amounts of β- lactamase constitutively. C. Failure to bind to penicillin binding proteins, in gram negative and gram positive organisms. V. ANTIMICROBIAL ACTIVITY The cephalosporins have been grouped into "generations" corresponding to their development by the pharmaceutical industry in response to clinical needs. In general, the later generations of cephalosporins have greater gram-negative activity at the expense of gram-positive activity. A. First generation agents Cefazolin Cephalothin Cephalexin (oral) Cefaclor (oral) All of these drugs inhibit gram-positive cocci (S.
  • Antimicrobial Use and Resistance (AUR) Module

    Antimicrobial Use and Resistance (AUR) Module

    February 2021 Antimicrobial Use and Resistance (AUR) Module Contents Antimicrobial Use and Resistance (AUR) Module ................................................................................. 1 Introduction .................................................................................................................................................. 1 1. Antimicrobial Use (AU) Option ................................................................................................................. 2 Introduction ......................................................................................................................................... 2 Requirements ....................................................................................................................................... 3 Data Analyses ....................................................................................................................................... 8 References .......................................................................................................................................... 14 Appendix A. Table of Instructions: Antimicrobial Use Option ........................................................... 15 Appendix B. List of Antimicrobials...................................................................................................... 17 Appendix C. Example Calculations of Antimicrobial Days .................................................................. 21 Appendix D: List of SAARsa ................................................................................................................